Introduction {#sec1-1}
============

Increased morbidity, mortality, and health-care cost are common complications from excessive postoperative bleeding.\[[@ref1]\]

The incidence of patients' reexploration in thoracic surgery for bleeding ranges from 1% to 3.7%, whereas the incidence for blood transfusion ranges from 20% to 52%.\[[@ref2][@ref3]\]

The serous membranes (pleura, pericardium, peritoneum, and meninges) when exposed to surgical insult, releases a high amount of plasminogen activators which result in increased local fibrinolytic activity and thus excessive bleeding occur.\[[@ref4][@ref5]\]

Tranexamic acid has been found to act either systemically or topically by binding to lysine binding sites of plasmin and plasminogen. Saturation of these sites blocks the attachment of plasminogen to fibrin thus inhibiting fibrinolysis.\[[@ref6][@ref7]\]

Systematic review and meta-analysis of randomized control trials showed that local application of tranexamic acid significantly decrease intraoperative blood loss in primary total hip replacement and reduce transfusion rates.\[[@ref8]\] Furthermore, other studies used tranexamic acid topically after coronary artery bypass graft and concluded that such topical application results in a decrease in postoperative blood loss without imposing extra risks on the patients.\[[@ref9]\]

The aim of this study is to evaluate the efficacy of local application of tranexamic acid in the pleural cavity after surgeries for decortication of the lung through open thoracotomy on postoperative blood loss.

Patients and Methods {#sec1-2}
====================

From January 2015 to May 2017, 70 patients underwent lung decortication surgery in Cardiothoracic Surgery Department, Tanta University Hospital.

After having the approval from the ethical committee at the university hospital, these group of patients were studied in a prospective, randomized, double-blind placebo controlled study.

All selected patients underwent decortication surgery for chronic thoracic empyema, encysted effusion, or clotted hemothorax on the elective way. We excluded all patients required lung resection, reopening due to surgical bleeding, patients requiring anticoagulant postoperatively for fear of deep vein thrombosis, patients with renal failure, patients with liver cirrhosis, primary blood disease such as hemophilia or else, know allergy to tranexamic acid, and pregnant female patients.

Patients were allocated into two groups, Group I (35 patients) received 3 g of tranexamic-acid in 100 ml of saline solution for proper distribution all over the thoracic cavity and Group II (35 patients) received 100 ml of saline solution as placebo in a double-blind way, in both groups, solution was distributed locally all over the pleural cavity at the end of operation and before closing the chest. The choice of the doses was decided on the arbitrary way, 3 g is an average dose between (1 and 5 g) that has been used in other studies.

Blocked randomization was used to divide the patients into two groups, each block consists of 35 patients, and all surgical team, circulating nurse, ward staff, and intensive care staff were blinded regarding the study population. The bottles either containing the tranexamic acid or placebo were prepared the day of surgery in a sterile way by the resident staff that has no role in the surgical procedure but start scrubbing after positioning of the patient and only helping the research work by delivering the bottles in a randomized way to the operating room.

Hemostasis was done, and the solution was poured into the pleural cavity immediately before closing the ribs and chest tubes were clamped the time needed for closure of the chest (30--45 min).

The total drainage was measured every 4 h in the first 24 h postoperatively in both groups then after that, chest tubes drainage is evaluated to differentiate by physical examination between blood and serosanguinous pleural fluid drainage.

Postoperative blood transfusion was given according to the following protocol, blood transfusion is not indicated when hemoglobin concentration is more than 10 g/dl. Blood transfusion is indicated when hemoglobin concentration is \<8 g/dl. Two units of the red cell should be transfused, and then, the clinical situation and hemoglobin concentration should be reassessed.

Blood transfusion is indicated in patients with hemoglobin between 8 and 10 g/dl if they are symptomatic or in patients who tolerate anemia poorly, for example, patients over 65 years or those with cardiovascular diseases or respiratory diseases.

We have followed the following protocol for chest tubes removal: removed sequentially, if no bleeding, no pus drainage, no air leakage, and pleural effusion drainage \<200 cc/day.

Intensive Care Unit (ICU) and hospital stay time were recorded.

Technique of study {#sec2-1}
------------------

Under general anesthesia, standard posterolateral thoracotomy in all patients and lung decortication was carried out for removal of all fibrous peel over the lung with or without pleurectomy.

Regular hemostasis performed and all bleeding points were secured.

Only before closure of the chest, 3 g of tranexamic acid diluted in 100 ml of normal saline and was distributed all over the pleural cavity for the Group I and in Group II, 100 ml of normal saline was used instead.

The chest was closed in layers with two chest tubes inserted for drainage and connected to underwater seal system.

Statistical analysis {#sec2-2}
--------------------

The collected data were organized, tabulated and statistically analyzed using the Statistical Package for the Social Sciences software (SPSS, IBM, Chicago, USA) version 22. For quantitative data, the range, mean and standard deviation were calculated. For qualitative data, the comparison between two groups and more was done using Chi-square test. For comparison between means of two groups of parametric data, Student\'s *t*-test was used.

Results {#sec1-3}
=======

There were seventy patients included in the study, 35 patients in Group I and 35 patients in Group II.

Both groups were comparable and showed no significant differences regarding their age, sex, and surgical indication for decortication \[[Table 1](#T1){ref-type="table"}\].

###### 

Demographic data and indication for surgery

                                     Group I       Group II      Test            *P*
  ---------------------------------- ------------- ------------- --------------- -------
  Age                                                                            
   Range                             18-68         19-69         *T*: 0.911      0.343
   Mean±SD                           41.97±14.65   45.20±13.64                   
  Sex (%)                                                                        
   Male                              21 (60)       20 (57.1)     *χ*^2^: 0.059   0.808
   Female                            14 (40)       15 (42.9)                     
  Indication for decortication (%)                                               
   Chronic empyema                   21 (60)       26 (74.3)     *χ*^2^: 1.624   0.444
   Clotted hemothorax                8 (22.9)      5 (14.3)                      
   Encysted effusion                 6 (17.1)      4 (11.4)                      

SD: Standard deviation

No significant difference between both groups regarding ICU stay and hospital stay were noted \[[Table 2](#T2){ref-type="table"}\]. However, patients in Group I had significant better hemoglobin level during the first and second day postoperatively (*P* = 0.019 and 0.001), and received lesser units of blood transfusion (*P* = 0.001).

###### 

Blood transfusion, Intensive Care Unit and hospital stay, pre- and post-operative hemoglobin

                           Group I      Group II     Test          *P*
  ------------------------ ------------ ------------ ------------- ---------
  Blood transfusion                                                
   Range                   0-2          0-3          *T*: 12.814   0.001\*
   Mean±SD                 0.69±0.90    1.54±1.09                  
  ICU stay                                                         
   Range                   1-3          1-3          *T*: 0.633    0.429
   Mean±SD                 1.34±0.59    1.46±0.61                  
  Hospital stay                                                    
   Range                   4-9          4-9          *T*: 0.593    0.444
   Mean±SD                 6.11±1.51    6.40±1.59                  
  Preoperative Hgb                                                 
   Range                   10-11.5      10-11        *T*: 1.573    0.214
   Mean±SD                 10.59±0.43   10.47±0.35                 
  Hgb in the first 24 h                                            
   Range                   7.5-10       7.5-10       *T*: 5.804    0.019\*
   Mean±SD                 8.81±0.81    8.36±0.74                  
  Hgb in the second 24 h                                           
   Range                   8.4-9.7      8-9.5        *T*: 11.649   0.001\*
   Mean±SD                 8.93±0.44    8.56±0.46                  

Hgb: Hemoglobin, SD: Standard deviation, ICU: Intensive Care Unit, \*: Statistically significant at *P* ≤ 0.05

In spite of both groups had no statistically significant differences in the amount of blood loss during the surgical procedures \[[Table 3](#T3){ref-type="table"}\]. Group I had statistically significant lesser amount of postoperative blood loss starting from immediate postoperative time (4 h) and continued lesser in all the measurements up to 48 h postoperatively \[[Table 2](#T2){ref-type="table"} and [Figure 1](#F1){ref-type="fig"}\].

###### 

Intraoperative and postoperative blood loss

  Blood loss       Group I         Group II        *t*-test   *P*
  ---------------- --------------- --------------- ---------- ---------
  Intraoperative                                              
   Range           200-550         200-500         0.052      0.821
   Mean±SD         340.0±114.28    334.29±95.31               
  Post 4 h                                                    
   Range           50-200          100-250         20.799     0.001\*
   Mean±SD         115.50±41.99    180.50±47.96               
  Post 8 h                                                    
   Range           70-300          130-300         15.078     0.001\*
   Mean±SD         150.00±56.85    218.50±54.70               
  Post 12 h                                                   
   Range           80-350          170-360         15.465     0.001\*
   Mean±SD         179.50±65.01    258.50±62.01               
  Post 16 h                                                   
   Range           100-450         200-430         13.499     0.001\*
   Mean±SD         209.00±78.93    297.00±72.41               
  Post 20 h                                                   
   Range           120-500         240-500         14.326     0.001\*
   Mean±SD         239.00±86.63    340.50±82.94               
  Post 24 h                                                   
   Range           130-500         280-550         18.212     0.001\*
   Mean±SD         267.50±86.93    385.00±87.21               
  Post 48 h                                                   
   Range           200-700         400-850         30.342     0.001\*
   Mean±SD         382.50±119.51   632.50±164.06              

SD: Standard deviation, \*: Statistically significant at *P* ≤ 0.05

![Intraoperative and postoperative blood loss](ACA-21-409-g001){#F1}

Discussion {#sec1-4}
==========

A phenomenon of activation of fibrinolysis during and after surgical intervention is a well-known phenomenon. The surgical trauma to the serous membrane, operative blood loss with consumption of clotting factors and platelet, and administration of crystalloids and or colloids during or after the surgery, all are precipitating factors for activation of fibrinolysis cascade.\[[@ref10][@ref11][@ref12]\]

Decortication surgery of the lung is one of the best examples of cases where patients may suffer this phenomenon.

Hence, using antifibrinolytic therapy postoperatively to minimize such bleeding is indicated and has proved its efficacy in the field of cardiothoracic surgery. To minimize the side effects of the thrombotic tendency by systemic infusion, local administration of tranexamic acid has been studied in cardiac and noncardiac surgery with encouraging results.\[[@ref9][@ref13]\]

A dose of 1 g of tranexamic acid in 100 ml saline was used both by De Bonis *et al*.\[[@ref14]\] and Fawzy *et al*.\[[@ref9]\] in their study in patients undergoing coronary artery bypass graft surgery before closing the chest with very favorable results with significant reduction of postoperative bleeding.

In our study, we used 3 g of tranexamic acid in 100 ml saline before closing the chest after decortication surgery. We used larger amount than open heart surgery because the raw surface area after decortication surgery is larger and we did not report any side effect of such doses but rather a significant clinical and statistical reduction in postoperative bleeding in the first 48 h postoperatively in patients in Group I than patients in Group II.

Dell'Amore *et al*. in 2012 used the tranexamic acid after thoracic surgery (resection surgeries) in topical form by pouring 5 g of tranexamic acid in 100 saline before closing the chest and proved its statistical and clinical effect in reducing the postoperative bleeding in this group of patients in comparison to other group of patients who received a placebo in the form of 100 ml saline.\[[@ref15]\] They reported that no side effects due to such doses.

So which dose is the best, more effective and safe is not clear until now, but in the literature, it has been hypothesized that topical antifibrinolytic agents directly target the source of bleeding and reducing the local activation of the fibrinolytic process.\[[@ref5]\]

We proved the effective role of the topical use of tranexamic acid in reducing the postoperative bleeding after decortication surgery of the lung (*P* = 0.001) associated with significant reduction in blood transfusion, even if there was no significant impact on ICU or hospital stay.

Conclusion {#sec1-5}
==========

The local intrapleural use of tranexamic acid after decortication surgery of the lung is safe and significantly reduces the amount of postoperative blood loss and in consequence, reduces the amount of postoperative blood transfusion.

Study limitations {#sec2-3}
-----------------

The study population needs to be on a larger scale to have more powered results, and the dose of tranexamic acid is somewhat arbitrary and needs to be more sharply defined.
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